Labori K J, Guren M G, Brudvik K W, Røsok B I, Waage A, Nesbakken A, Larsen S, Dueland S, Edwin B, Bjørnbeth B A
Department of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
Department of Oncology, Oslo University Hospital, Oslo, Norway.
Colorectal Dis. 2017 Aug;19(8):731-738. doi: 10.1111/codi.13622.
There is debate as to the correct treatment algorithm sequence for patients with locally advanced rectal cancer with liver metastases. The aim of the study was to assess safety, resectability and survival after a modified 'liver-first' approach.
This was a retrospective study of patients undergoing preoperative radiotherapy for the primary rectal tumour, followed by liver resection and, finally, resection of the primary tumour. Short-term surgical outcome, overall survival and recurrence-free survival are reported.
Between 2009 and 2013, 45 patients underwent liver resection after preoperative radiotherapy. Thirty-four patients (76%) received neoadjuvant chemotherapy, 24 (53%) concomitant chemotherapy during radiotherapy and 17 (43%) adjuvant chemotherapy. The median time interval from the last fraction of radiotherapy to liver resection and rectal surgery was 21 (range 7-116) and 60 (range 31-156) days, respectively. Rectal resection was performed in 42 patients but was not performed in one patient with complete response and two with progressive metastatic disease. After rectal surgery three patients did not proceed to a planned second stage liver (n = 2) or lung (n = 1) resection due to progressive disease. Clavien-Dindo ≥Grade III complications developed in 6.7% after liver resection and 19% after rectal resection. The median overall survival and recurrence-free survival in the patients who completed the treatment sequence (n = 40) were 49.7 and 13.0 months, respectively. Twenty of the 30 patients who developed recurrence underwent further treatment with curative intent.
The modified liver-first approach is safe and efficient in patients with locally advanced rectal cancer and allows initial control of both the primary tumour and the liver metastases.
对于局部晚期直肠癌伴肝转移患者的正确治疗算法顺序存在争议。本研究的目的是评估改良“肝优先”方法后的安全性、可切除性和生存率。
这是一项对接受原发性直肠肿瘤术前放疗、随后进行肝切除、最后切除原发性肿瘤的患者的回顾性研究。报告了短期手术结果、总生存率和无复发生存率。
2009年至2013年期间,45例患者在术前放疗后接受了肝切除。34例患者(76%)接受了新辅助化疗,24例(53%)在放疗期间接受了同步化疗,17例(43%)接受了辅助化疗。从放疗最后一次分割到肝切除和直肠手术的中位时间间隔分别为21天(范围7 - 116天)和60天(范围31 - 156天)。42例患者进行了直肠切除,但1例完全缓解患者和2例疾病进展的转移患者未进行直肠切除。直肠手术后,3例患者因疾病进展未进行计划中的第二阶段肝(n = 2)或肺(n = 1)切除。肝切除后Clavien-Dindo≥Ⅲ级并发症发生率为6.7%,直肠切除后为19%。完成治疗序列的患者(n = 40)的中位总生存率和无复发生存率分别为49.7个月和13.0个月。30例复发患者中有20例接受了旨在治愈的进一步治疗。
改良肝优先方法对于局部晚期直肠癌患者是安全有效的,能够对原发性肿瘤和肝转移灶进行初始控制。